RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Ezetimibe Plus Statin Reduces CV Events after ACS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 52
SP 17
OP 18
DO 10.1177/155989771452009
UL http://mdc.sagepub.com/content/14/52/17.abstract
AB Statins have been demonstrated to reduce morbidity and mortality; however, adding other lipid-modifying therapies to statin treatment has not demonstrated a clear benefit. This article presents data from the Improved Reduction of Outcomes: Vytorin (Ezetimibe/Simvastatin) Efficacy International Trial [IMPROVE-IT; NCT00202878]. The purpose of the IMPROVE-IT trial was to evaluate the clinical benefit of combination therapy with ezetimibe plus simvastatin compared with simvastatin monotherapy in lowering LDL-C levels.